Asia Deal Watch: FujiFilm, Hisun Team To Develop Flu Drug For Chinese Market
Agreement between FujiFilm and Hisun sets plan for developing the novel flu drug Avigan in China. Also, CANbridge and WuXi partner in rare diseases, and Kissei gets Asian rights to Rigel’s Tavalisse.
You may also be interested in...
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Asajes Ventures sees itself as offering a unique new mixed business model of venture capital and local development activity for smaller Western companies looking to develop their product or pipeline assets in Japan and China, aided by new opportunities from a rapidly reforming regulatory environment.
Takeda may have to shed a Shire late-stage pipeline asset to meet European anti-competition concerns around the companies' planned merger, although the process is not expected to derail the deal's timing.